CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia

ABSTRACT:

SUBMITTER: Gang M 

PROVIDER: S-EPMC12293095 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature